Published in Mol Pharmacol on September 30, 2015
Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2. Cell Cycle (2016) 0.77
NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo. J Hematol Oncol (2016) 0.76
Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients? Oncotarget (2016) 0.75
Hypoxia Regulates mTORC1-Mediated Keratinocyte Motility and Migration via the AMPK Pathway. PLoS One (2017) 0.75
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. Oncotarget (2017) 0.75
AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of in vitro osteogenic differentiation. Biochim Biophys Acta (2017) 0.75
Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in retinal pigment epithelial cells. PLoS One (2017) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 7.77
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
LKB1-dependent signaling pathways. Annu Rev Biochem (2006) 5.91
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci (2007) 4.07
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
The ancient drug salicylate directly activates AMP-activated protein kinase. Science (2012) 3.77
Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem (1998) 3.53
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell (1993) 3.17
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene (2009) 3.09
AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci (2005) 3.04
Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle (2010) 2.61
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res (2009) 1.95
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev (2012) 1.67
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle (2010) 1.60
The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res (2002) 1.49
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci (2008) 1.45
AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans (2011) 1.39
Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer (2009) 1.38
Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene (2009) 1.34
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.33
Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res (2010) 1.21
AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol (2012) 1.16
AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem (2008) 1.08
Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. J Immunol (1991) 1.06
AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res (2014) 1.04
AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol (2013) 0.93
Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One (2014) 0.93
Metformin, an old drug, brings a new era to cancer therapy. Cancer J (2015) 0.90
ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett (2012) 0.89
Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation. Am J Pathol (2015) 0.88
Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. Int J Mol Med (2014) 0.87
Augmented AMPK activity inhibits cell migration by phosphorylating the novel substrate Pdlim5. Nat Commun (2015) 0.87
Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun (2014) 0.84
Metformin reduces TGF-β1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Otolaryngol Head Neck Surg (2014) 0.83
AMP-activated protein kinase is required for induction of apoptosis and epithelial-to-mesenchymal transition. Cell Signal (2010) 0.82
The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling. J Hepatol (2013) 0.81